Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis

Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors

(2022) Neal S. Chawla et al.   Clinical Genitourinary Cancer

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

(2021) Ivan de Kouchkovsky et al.   Journal for ImmunoTherapy of Cancer

Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma

(2021) Yujiro Hayashi et al.   Frontiers in Oncology

Clinicopathological and prognostic significance of preoperative plasma fibrinogen level in patients with upper urinary tract urothelial carcinoma: A retrospective tumor marker prognostic study

(2019) Rongzong Liu et al.   International Journal of Surgery

Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer

(2019) Jenny Roggisch et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

The evolution of bladder cancer genomics: What have we learned and how can we use it?

(2018) François Audenet et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Epidemiology of urothelial carcinoma

(2017) Jun Miyazaki et al.   INTERNATIONAL JOURNAL OF UROLOGY

Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications

(2016) Boaz Kurtis et al.   Annals of Diagnostic Pathology

Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change

(2016) Liang Cheng et al.   HISTOPATHOLOGY

Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis

(2016) Ping Yuan et al.   PLoS One

TERT Core Promotor Mutations in Early-Onset Bladder Cancer

(2016) Johannes Giedl et al.   Journal of Cancer

Mutations inTERTpromoter andFGFR3and telomere length in bladder cancer

(2015) Ismail Hosen et al.   INTERNATIONAL JOURNAL OF CANCER

Telomerase Reverse Transcriptase Gene Promoter Mutations Help Discern the Origin of Urogenital Tumors: A Genomic and Molecular Study

(2013) Song Wu et al.   EUROPEAN UROLOGY

Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome

(2013) Yves Allory et al.   EUROPEAN UROLOGY

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism

(2013) P. S. Rachakonda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of the human catalytic subunit of telomerase (hTERT)

(2012) Michael Daniel et al.   GENE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract

(2010) Sylvia Scarpini et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Immunoexpression and prognostic role of hTERT and cyclin D1 in urothelial carcinoma

(2008) CHING-HSIU YANG et al.   APMIS